Skip to main content

Home/ Cancer/ Group items tagged VDR

Rss Feed Group items tagged

Matti Narkia

The Relevance of Vitamin D Receptor (VDR) Gene Polymorphisms for Cancer: A Review of th... - 0 views

  •  
    The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature.
    Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J.
    Anticancer Res. 2009 Sep;29(9):3511-36. Review.
    PMID: 19667145

    CONCLUSION: Significant associations with VDR polymorphisms have been reported in cancer of the breast (Fok1, Bsm1, Taq1, Apa1, poly (A)), prostate (Fok1, Bsm1, Taq1, poly (A)), skin (Fok1, Bsm1, A-1210), colorectum (Fok1, Bsm1), ovary (Fok1, Apa1) and bladder (Fok1), and in renal cell carcinoma (Taq1, Apa1). However, conflicting data have been reported for most malignancies. After careful evaluation of the actual literature, it can be summarized that data indicating an association of VDR polymorphisms and cancer risk are strongest for breast cancer (Bsm1, Fok1), prostate cancer (Fok1) and malignant melanoma (MM) (Fok1). Data indicating an association of VDR polymorphisms and cancer prognosis are strongest for prostate cancer (Fok1), breast cancer (Bsm1, Taq1), MM (Bsm1) and renal cell carcinoma (Taq1).
Matti Narkia

Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk -- Raimond... - 0 views

  •  
    Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk.
    Raimondi S, Johansson H, Maisonneuve P, Gandini S.
    Carcinogenesis. 2009 Jul;30(7):1170-80. Epub 2009 Apr 29. Review.
    PMID: 19403841
Matti Narkia

Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy - 0 views

  •  
    Vitamin D and intervention trials in prostate cancer: from theory to therapy.
    Schwartz GG.
    Ann Epidemiol. 2009 Feb;19(2):96-102. Epub 2008 Jul 10.
    PMID: 18619854
    doi:10.1016/j.annepidem.2008.03.007

    This suggests that whereas vitamin D (e.g., cholecalciferol) might prevent prostate cancer, existing prostate tumors likely would require treatment with 1,25(OH)(2)D and/or its analogs. The major obstacle to the use of 1,25(OH)(2)D in patients therapeutically is the risk of hypercalcemia. Several maneuvers to reduce this risk, including pulse dosing and the use of less calcemic 1,25(OH)(2)D analogs, have been explored in Phase I-III clinical trials. Once merely a promise, vitamin D-based therapies for prostate cancer may soon be medical practice.
Matti Narkia

Vitamin D and cancer Ali MM, Vaidya V - J Can Res Ther 2007 Oct-Dec - 0 views

  •  
    Vitamin D and cancer.
    Ali MM, Vaidya V.
    J Cancer Res Ther. 2007 Oct-Dec;3(4):225-30. Review.
    PMID: 18270398
    DOI: 10.4103/0973-1482.38998
Matti Narkia

MedWire News - Oncology - Vitamin D induces potential breast-tumor suppressor - 0 views

  •  
    MedWire News: Calcitriol, the active form of vitamin D, has been found to induce the tumor-suppressing protein CCAAT enhancer-binding protein (C/EBP)α, which can inhibit the growth of breast cancer cells, researchers report.
1 - 5 of 5
Showing 20 items per page